Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cost-effectiveness of 14-day vonoprazan-based quadruple therapy for H. pylori eradication in high clarithromycin and levofloxacin resistance area
TCTR20230428003Phase 4Completed
- Sponsor
- Center of Excellence in Digestive Diseases, Thammasat University
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of vonoprazan in Helicobacter pylori infection, sponsored by Center of Excellence in Digestive Diseases, Thammasat University. Started Jul 2021; status: completed.
02
Drugs
vonoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on TCTR20230428003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20230428003.